Detail akcie GB Sciences Rg online

Business Summary: GB Sciences, Inc., formerly Growblox Sciences, Inc., is engaged in developing and utilizing technologies in plant biology, cultivation and extraction techniques combined with biotechnology, and plans to produce medical-grade cannabis, cannabis concentrates and cannabinoid therapies. It seeks to be a technology and solution company that converts the cannabis plant into medicines, therapies and treatments for a range of ailments. It intends to conduct its business operations, through its subsidiaries in approximately three operating units, which include Solutions, Sciences and Product divisions. The Solutions division involves the development and use of its suite of controlled-climate indoor agricultural technology growing and cultivation Suites, including TissueBLOX, GrowBLOX, CureBLOX and ExtractionLAB. The Science division is engaged in preclinical testing of its biopharmaceutical cannabinoid product prototypes to begin future human clinical trials.
Financial Summary: BRIEF: For the three months ended 30 June 2019, GB Sciences Inc revenues decreased 31% to $911K. Net loss decreased 53% to $2.4M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Lower net loss reflects General and administrative expenses decrease of 49% to $2.3M (expense), Interest expense decrease of 71% to $500K (expense).